Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Investor Presentation (August 2025)
21 slides from Aethlon Medical's investor presentation, Aug 21, 2025
Slide 1: Corporate Presentation: The Hemopurifier
Corporate Presentation The Hemopurifier®
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS 2 This investor presentation contains forward - looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934
Slide 3: Investment Highlights
Investment Highlights 3 • Patented Aethlon Hemopurifier® blood purification device • Early clinical trials have shown enveloped virus and extracellular vesicle (EV*) clearance both in vitro and in patients • Two FDA “Breakthrough Device” designations • Advanced/metastatic cancer • Life - threatening
Slide 4: The Aethlon Hemopurifier
The Aethlon Hemopurifier® » Administered in 167 Hemopurifier sessions in 41 patients with a favorable safety profile 1 » Proprietary, patented technology » Demonstrated clearance of life - threatening enveloped viruses » Designed to clear tumor - derived EVs, and their associated cargo (Oncology) 1
Slide 5: Unique Mechanism of Action
Unique Mechanism of Action How It Works: • Plasma separation: Obviates the need for plasmapheresis or plasma exchange • Size exclusion: Keeps larger, unwanted particles within the lumen of the device while allowing smaller targets to contact the proprietary affinity resin of the Hemopurifier • Targe
Slide 6: Hemopurifier Platform – Multi-Disease Potential
Hemopurifier Platform – Multi - Disease Potential Platform Enablers: Manufacturing, regulatory, IP foundation Enrolling in Australia: FDA Breakthrough Device Oncology 6 Life Threatening Viral Infections Exploratory Indications (Platform Potential) Preclinical/clinical - readiness; FDA Breakthrough D
Slide 7: Oncology
Oncology aethion/@)
Slide 8: Why the Hemopurifier Targets Tumor-Derived EVs
Why the Hemopurifier Targets Tumor - Derived EVs Extracellular Vesicles (EVs) including small EVs known as exosomes (50 - 150nm) are lipid bilayer enclosed nanoparticles released by all cell types including tumor cells » EVs are involved in cell - to - cell communication » Extracellular Vesicles con
Slide 9: Immunotherapy Market & Unmet Need
Immunotherapy Market & Unmet Need Market Size • PD - 1/PD - L1 Inhibitors: ~$62B in 2025 → ~$120B by 2030 • Checkpoint Inhibitors (PD - 1, PD - L1, CTLA - 4): ~$26B in 2024 → ~$107B by 2034 • PD - 1 Inhibitor Drugs: ~$48.7B in 2025 → ~$179.8B by 2034 Response Challenge Only 30 - 40% have a lasting c
Slide 10: In Vitro Removal Of Cancer-Derived EVs Demonstrated
In Vitro Removal Of Cancer - Derived EVs Demonstrated 10 In Vitro Experiments (Miniature Hemopurifier): • Multiple Tumor Types – Removed 92 - 99 % of buffer suspended EVs (Marleau AM , Jacobs MT, Gruber N, e t al . Cance r Res 2020 ; 80 ( 16 _Supplement) : 4509 . ) • Patient Plasma – Removed EVs dir
Slide 11: In Vivo Reduction of Exosomes in Head & Neck Cancer
In Vivo Reduction of Exosomes in Head & Neck Cancer Single subject with head and neck cancer following 2 distinct Hemopurifier treatments » The total nanoparticle counts decreased following each of the treatments. » Slowly rose 7 days following the treatment to levels that were below the baseline me
Slide 12: Progress in Australian Hemopurifier Oncology Trial
12 Progress in Australian Hemopurifier® Oncology Trial Trial Status • 3 sites open as of February 2025 • 3 participants received a single HP treatment in Cohort 1 • Protocol amendment broadens participant eligibility to allow all treatment regimens that include an anti PD - 1 agent • Cohort 2 now op
Slide 13: Virology
Virology aethion/@)
Slide 14: Hemopurifier for Emerging Viral Threats
Hemopurifier® for Emerging Viral Threats Source: World Health Organization: Prioritizing diseases for research and development in emergency contexts 14 We believe the Aethlon Hemopurifier® is Uniquely Positioned as an Early Treatment Option for Future Bioattacks or Pandemic Threats » The next bioatt
Slide 15: In Vitro and In Vivo Removal of Enveloped Viruses
In Vitro and In Vivo Removal of Enveloped Viruses • Hepatitis C • Ebola • Marburg • Dengue • Chikungunya • HIV • Ebola • SARs - CoV - 2 15 • West Nile Virus • H5N1 (Bird Flu) • 1918 Spanish Flu • EBV • MERS - CoV • SARs - CoV - 2 Spike Protein • SARs - CoV2 (7 variants) In vitro: • HIV In vivo (Huma
Slide 16: Pre-Clinical Research - Long COVID
Pre - Clinical Research - Long COVID Background: • Long COVID is the persistence of symptoms at least 3 months following acute infection with the SARS - CoV - 2 virus • Global incidence of Long COVID is estimated to be 400,000,000 with an economic burden of 1 trillion dollars/year (Nat Med 30, 2148
Slide 17: Pre-Clinical - Platelet-Derived Microparticles
Pre - Clinical - Platelet - Derived Microparticles (MPs) Background: • Microparticles derived from activated platelets (PD - EVs) are elevated in a myriad of diseases and associated with disease activity: • SLE (Lupus) • Rheumatoid Arthritis • Cancer • Systemic Sclerosis • Multiple Sclerosis • Alzhe
Slide 18: Pre-Clinical - Organ Transplantation
Pre - Clinical - Organ Transplantation Background: • Machine Perfusion (MP) following kidney recovery improves outcomes compared to static cold storage • MP is associated with the release of EVs and microRNAs, which are linked to delayed graft function and acute rejection Hypothesis: The Hemopurifie
Slide 19: International Patent Protection
United States International Patent Protection Extending to 2044 (Including Pending Applications) Issued Patents: • 3 patents issued covering extracorporeal removal of microvesicular particles, patent protection until 2029 • 1 patent to be issued (issue fee paid) covering treatment of coronavirus inf
Slide 20: Key Financial Highlights
Key Financial Highlights 20 » Cash Position: ~ $3.8 million in cash as of June 30, 2025, funding near term operations and clinical development » Debt - Free Balance Sheet: No outstanding debt, maintaining financial flexibility » Capital Structure: ~2.6 million shares outstanding as of August 2025, f
Slide 21: Contact Information
11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD wwwˌAethlonMedicalˌcom 21 This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including: whether and when our products may be succe
Aethlon Medical — Investor Presentation (August 2025) on 6ix